ClinicalTrials.gg
CompletedNCT03405259Updated Jun 17, 2019Results posted

A Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity

An interventional study of Super Seal® Desensitizer and Acclean® Fluoride Varnish in Dentinal Hypersensitivity, sponsored by Procter and Gamble. Completed. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-17.

Sponsored by Procter and Gamble · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 6 months after the study started (first participant enrolled Jun 2013, registered Jan 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to compare professional treatments for dentinal hypersensitivity immediately following a single, professionally-applied treatment and again approximately 2 months following treatment.

02

Conditions studied

  • Dentinal Hypersensitivity
03

In context

Lead sponsor

Procter and Gamble is the lead sponsor of 83 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years of age;
  • provide written prior to participation and be given a signed copy of the informed consent form;
  • be in good general health as determined by the Investigator/designee; and
  • have at least one tooth with a VAS score of greater than or equal to 30 in response to the air challenge.

Exclusion criteria

Exclusion Criteria:

  • allergy to rosin or to pine nuts;
  • self-reported pregnancy or nursing;
  • severe periodontal disease, as characterized by purulent exudate, generalized mobility, and/or severe recession;
  • active treatment for periodontitis;
  • fixed facial orthodontic appliances;
  • any diseases or conditions that might interfere with the safe completion of the study; or
  • an inability to undergo any study procedures.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    Super Seal® Desensitizer

    Professionally Applied

    Device: Super Seal® Desensitizer

  • Sham comparator
    Acclean® Fluoride Varnish

    Professionally Applied

    Device: Acclean® Fluoride Varnish

Interventions

  • DeviceSuper Seal® Desensitizer

    Single dose professional application.

  • DeviceAcclean® Fluoride Varnish

    Single dose professional application.

06

What researchers measure

Primary outcomes

  1. Change From Baseline Air Challenge

    The Schiff Sensitivity Scale was assessed for each test tooth via an evaporative air challenge. The examiner recorded the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows- 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subject responds to stimulus and requests discontinuation or moves form stimulus, 3: tooth/subject responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A negative change from Baseline score represents a decrease in sensitivity from baseline.The mean change from Baseline was calculated for this measure.

    Time frame: Within 5 minutes after treatment was applied

  2. Change From Baseline Visual Analog Scale

    Visual Analog Scale (VAS) - subjects are asked to look at a VAS and designate the level of hypersensitivity they experienced as a result of the thermal and water challenges using a continuum scale of 0 = No tooth pain up to 100 = Worst tooth pain ever experienced. A negative change from Baseline score represents a decrease in sensitivity from baseline.

    Time frame: Within 5 minutes after treatment was applied

07

Results

Posted Jun 17, 2019

Participant flow

Participant flow — Overall Study
MilestoneSuper Seal® DesensitizerAcclean® Fluoride Varnish
Started1111
Completed1111
Not completed00

Outcome measures

PrimaryChange From Baseline Air Challenge

The Schiff Sensitivity Scale was assessed for each test tooth via an evaporative air challenge. The examiner recorded the Schiff Index score corresponding to the response to the air challenge. The Schiff Index Sensitivity scale is scored as follows- 0: tooth/subject did not respond to stimulus, 1: tooth/subject responds to stimulus, but does not request discontinuation of stimulus, 2: tooth/subject responds to stimulus and requests discontinuation or moves form stimulus, 3: tooth/subject responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A negative change from Baseline score represents a decrease in sensitivity from baseline.The mean change from Baseline was calculated for this measure.

Time frame:
Within 5 minutes after treatment was applied
Reported as:
Mean · Units on a scale
Change From Baseline Air Challenge
Units on a scaleSuper Seal® DesensitizerAcclean® Fluoride Varnish
Change From Baseline Air Challenge-0.55 ± 0.69-0.95 ± 0.93
PrimaryChange From Baseline Visual Analog Scale

Visual Analog Scale (VAS) - subjects are asked to look at a VAS and designate the level of hypersensitivity they experienced as a result of the thermal and water challenges using a continuum scale of 0 = No tooth pain up to 100 = Worst tooth pain ever experienced. A negative change from Baseline score represents a decrease in sensitivity from baseline.

Time frame:
Within 5 minutes after treatment was applied
Reported as:
Mean · Units on a scale
Change From Baseline Visual Analog Scale
Units on a scaleSuper Seal® DesensitizerAcclean® Fluoride Varnish
Change From Baseline Visual Analog Scale-17.60 ± 21.32-19.55 ± 25.15

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Super Seal® Desensitizer0/11 (0%)0/11 (0%)0/11 (0%)
Acclean® Fluoride Varnish0/11 (0%)0/11 (0%)0/11 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Super Seal® DesensitizerAcclean® Fluoride VarnishTotal
<=18 years000
Between 18 and 65 years111122
>=65 years000
Age, Continuous
Age, Continuous(years)Super Seal® DesensitizerAcclean® Fluoride VarnishTotal
Mean44.6 ± 9.8448.1 ± 19.7146.4 ± 15.30
Sex: Female, Male
Sex: Female, Male(Participants)Super Seal® DesensitizerAcclean® Fluoride VarnishTotal
Female91120
Male202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Super Seal® DesensitizerAcclean® Fluoride VarnishTotal
Asian Oriental112
Black011
Caucasian8917
Hispanic202
Region of Enrollment
Region of Enrollment(participants)Super Seal® DesensitizerAcclean® Fluoride VarnishTotal
United States111122
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2013 to primary completion in Sep 2013, 2 months.

Results were first posted in Jun 2019, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2018
First posted
Jan 23, 2018
StartActual
Jun 26, 2013
Primary completionActual
Sep 13, 2013
CompletionActual
Sep 13, 2013
Results first posted
Jun 17, 2019
Last update
Jun 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03405259
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Jan 23, 2018
Start date
Jun 26, 2013
Primary completion
Sep 13, 2013
Completion
Sep 13, 2013
Results posted
Jun 17, 2019
Last update
Jun 17, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion